Nurix Therapeutics, Inc. Stock Price, News & Analysis

Nurix Therapeutics (NASDAQ: NRIX) announced a clinical update for its ongoing Phase 1 trial of NX-2127, a targeted protein degrader for patients with hematologic malignancies. The updates will be presented at the 64th American Society of Hematology Annual Meeting from December 10-13, 2022. Dr. Anthony Mato of Memorial Sloan Kettering Cancer Center will give an oral presentation on chronic lymphocytic leukemia (CLL) patients. NX-2127 degrades Bruton’s tyrosine kinase (BTK) and is currently under evaluation in clinical trials.

Nurix Therapeutics (Nasdaq: NRIX), a biopharmaceutical company focused on developing targeted protein modulation therapies for cancer, announced key participation in November conferences. CEO Arthur T. Sands will present at:

• Credit Suisse 31^st Annual Healthcare Conference on November 8, 11:25 - 11:55 a.m. ET.
• Piper Sandler 34^th Annual Healthcare Conference on November 30, 4:30 - 4:55 p.m. ET.

The events will be webcast and available on the company's website for about 30 days afterward.

Nurix Therapeutics (Nasdaq: NRIX) announced promising initial results from the NX-2127 clinical trial for patients with diffuse large B cell lymphoma (DLBCL). A patient achieved a complete response at 8 weeks, confirmed at 16 weeks, after receiving 300 mg of NX-2127 daily. This dual-action drug targets Bruton’s tyrosine kinase (BTK) and aids in degrading key proteins linked to tumor proliferation. The NX-2127 trial shows potential for addressing unmet medical needs in aggressive lymphomas, with further updates expected at the upcoming American Society of Hematology meeting in December.

Nurix Therapeutics (Nasdaq: NRIX) announced plans to present at the 5th Annual TPD Summit from October 25-28, 2022, in Boston, MA. A Keynote Plenary will be delivered by Arthur T. Sands, M.D., Ph.D., the CEO, discussing advancements in BTK degraders for hematologic malignancies. Other presentations include topics on targeted protein degradation and orally active, brain-penetrant degraders. Nurix focuses on developing therapies that modulate cellular protein levels, utilizing their DELigase discovery platform.

Nurix Therapeutics reported Q3 2022 results, highlighting a gross revenue of $10.8 million, up from $10.3 million in Q3 2021. The company raised $95 million from two registered direct offerings in July, bolstering its cash position to $413.6 million as of August 31, 2022. R&D expenses rose to $47.8 million, reflecting increased clinical activities, while net loss was $45.7 million or $0.90 per share. Nurix expanded its leadership team and announced six presentations at the SITC 2022 annual meeting, including initial data for its NX-1607 program.

Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced six poster presentations for the Society for Immunotherapy of Cancer’s 37th Annual Meeting from November 8-12, 2022, in Boston. The presentations highlight the company’s targeted protein modulation platform and CBL-B inhibitors, including NX-1607 and DeTIL-0255. Key data to be presented includes initial biomarker data from a Phase 1 trial of NX-1607 in patients with advanced malignancies. These advancements could enhance anti-tumor immunity and broaden treatment options for various cancer types.

Nurix Therapeutics, Inc. (Nasdaq: NRIX) has appointed Edward C. Saltzman to its board of directors, enhancing its strategic capabilities in drug development. With over 30 years of experience in the biopharmaceutical sector, Saltzman currently leads Biotech Strategy at Lumanity Inc. His expertise is expected to significantly contribute as Nurix advances its drug pipeline targeting cancer treatments. CEO Arthur T. Sands expressed optimism about Saltzman's role in the company's growth, specifically highlighting Nurix’s DELigase platform designed to modulate protein levels for innovative cancer therapies.

Nurix Therapeutics (Nasdaq: NRIX) announced that Arthur T. Sands, M.D., Ph.D., will participate in two significant conferences in September 2022. The presentations include a Fireside chat at the Wells Fargo Healthcare Conference on September 7 from 3:45 to 4:15 p.m. ET, and another at the Baird 2022 Global Healthcare Conference on September 13 from 10:50 to 11:20 a.m. ET. These events will be webcast live, with recordings available for approximately 30 days. Nurix specializes in targeted protein modulation for treating cancer.

Nurix Therapeutics (Nasdaq: NRIX) announced the appointment of Eric Schlezinger as Chief People Officer. With extensive experience in biopharma HR, Schlezinger aims to enhance leadership and talent acquisition as Nurix expands its oncology pipeline. CEO Arthur Sands highlighted Schlezinger's strengths in building company culture and recruiting top talent. Previously, Schlezinger led HR at Adamas Pharmaceuticals and Vir Biotechnology, contributing to their growth and transitions to public companies. Nurix focuses on targeted protein modulation for cancer treatment, utilizing E3 ligases in their drug discovery.